Mefloquine plus artesunate — Competitive Intelligence Brief

Mefloquine plus artesunate (Mefloquine plus artesunate) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimalarial combination therapy. Area: Infectious Disease.

phase 3 Antimalarial combination therapy Infectious Disease Small molecule

Target snapshot

Mefloquine plus artesunate (Mefloquine plus artesunate) — Medicines for Malaria Venture. This combination uses mefloquine (a quinoline antimalarial) and artesunate (an artemisinin derivative) to kill malaria parasites through complementary mechanisms that reduce drug resistance.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Mefloquine plus artesunate TARGET	Mefloquine plus artesunate	Medicines for Malaria Venture	phase 3	Antimalarial combination therapy
Coadministered Artesunate plus Amodiaquine	Coadministered Artesunate plus Amodiaquine	Professor Anders Björkman	marketed	Antimalarial combination therapy	Plasmodium falciparum heme metabolism and protein synthesis
WHO-recommended periodic presumptive treatment	WHO-recommended periodic presumptive treatment	University of Washington	marketed	Antimalarial combination therapy
SP-IPTp	SP-IPTp	London School of Hygiene and Tropical Medicine	marketed	Antimalarial combination therapy	Plasmodium falciparum dihydrofolate reductase (sulfadoxine-pyrimethamine); hemozoin formation (piperaquine)
Amodiaquine-artesunate (ASAQ)	Amodiaquine-artesunate (ASAQ)	Centers for Disease Control and Prevention	marketed	Antimalarial combination therapy	Plasmodium falciparum heme polymerase; artemisinin-derived endoperoxide bridge
Artesunate plus Amodiaquine	Artesunate plus Amodiaquine	Bernhard Nocht Institute for Tropical Medicine	marketed	Antimalarial combination therapy	Plasmodium falciparum (multiple parasite targets including heme detoxification pathway and DNA synthesis)
lumefantrine plus artemether	lumefantrine plus artemether	Centers for Disease Control and Prevention	marketed	Antimalarial combination therapy	Malaria parasite heme metabolism and hemozoin formation

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimalarial combination therapy class)

1. London School of Hygiene and Tropical Medicine · 4 drugs in this class
2. Kenya Medical Research Institute · 2 drugs in this class
3. University of Oxford · 2 drugs in this class
4. Centers for Disease Control and Prevention · 2 drugs in this class
5. University of Melbourne · 1 drug in this class
6. Bernhard Nocht Institute for Tropical Medicine · 1 drug in this class
7. University of Washington · 1 drug in this class
8. Fundação de Medicina Tropical Dr. Heitor Vieira Dourado · 1 drug in this class
9. Medicines for Malaria Venture · 1 drug in this class
10. Professor Anders Björkman · 1 drug in this class